Results of autologous/syngeneic hematopoietic stem cell transplantation in patients with multiple sclerosis
| Group . | No. of patients* . | EDSS baseline . | Regimen . | Progressed . | Follow-up, mo, median (range) . | Treatment-related deaths . |
|---|---|---|---|---|---|---|
| Fassas et al190 191 | 24 | 6.0 (4.5-8.0) | BEAM + ATG | 5/23 | 40 (21-51) | 1 |
| Burt et al179,193 230 | 27 | 7.0 (3.0-8.5) | Cy/TBI | 4/25 | 14 (2-58) | 0 |
| Nash et al169 | 20 | 7.0 (5.0-8.0) | Cy/TBI/ATG | 2/13 | 5 (3-24) | 1 |
| Carreras et al232 | 10 | 6.2 (5.0-6.5) | BEAM + ATG | 2/10 | 18 (16-32) | 0 |
| Kozak et al189 | 8 | 6.5 (6.5-7.5) | BEAM + ATG | 1/8 | 8.5 (1-16) | 0 |
| Openshaw et al197 | 5 | 6.5 (5.5-7.5) | BU/Cy + ATG | 1/4 | 18 (17-30) | 2 |
| Mandalfino et al233 | 1 (identical twin) | 6.5 | Cy/TBI | 0/1 | 26 | 0 |
| Group . | No. of patients* . | EDSS baseline . | Regimen . | Progressed . | Follow-up, mo, median (range) . | Treatment-related deaths . |
|---|---|---|---|---|---|---|
| Fassas et al190 191 | 24 | 6.0 (4.5-8.0) | BEAM + ATG | 5/23 | 40 (21-51) | 1 |
| Burt et al179,193 230 | 27 | 7.0 (3.0-8.5) | Cy/TBI | 4/25 | 14 (2-58) | 0 |
| Nash et al169 | 20 | 7.0 (5.0-8.0) | Cy/TBI/ATG | 2/13 | 5 (3-24) | 1 |
| Carreras et al232 | 10 | 6.2 (5.0-6.5) | BEAM + ATG | 2/10 | 18 (16-32) | 0 |
| Kozak et al189 | 8 | 6.5 (6.5-7.5) | BEAM + ATG | 1/8 | 8.5 (1-16) | 0 |
| Openshaw et al197 | 5 | 6.5 (5.5-7.5) | BU/Cy + ATG | 1/4 | 18 (17-30) | 2 |
| Mandalfino et al233 | 1 (identical twin) | 6.5 | Cy/TBI | 0/1 | 26 | 0 |
EDSS indicates extended disability status score; BEAM, carmustine, etoposide, cytarabine, melphalan; ATG, antithymocyte globulin; Cy/TBI, cyclophosphamide and total body irradiation; and BU/Cy, busulfan and cyclophosphamide.
Actual patient number is based on updated communication with the author and may be higher than the number reported in the reference.